2 Information about finerenone
Marketing authorisation indication
2.1 Finerenone (Kerendia, Bayer) is indicated 'for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics for finerenone.